Erik Harris has sold RARE and made no open-market buys since Feb 2021

Erik Harris is the Executive Vice President and Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), where he oversees all worldwide commercial operations.( He joined the company in 2017 as Senior Vice President, Head of North American Commercial Operations, and was promoted to his current role in June 2019.(

Harris brings over 20 years of biopharmaceutical experience, including prior roles at Crescendo Bioscience as Vice President of Commercial, Vice President of Pulmonology Marketing at InterMune, and positions at Elan Pharmaceuticals, Genentech, and Bristol-Myers Squibb.( He has led launches of products such as Crysvita®, Mepsevii®, Dojolvi®, Tarceva®, Tysabri®, and Vectra-DA®.( His career began as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the U.S. Navy.( Harris holds an MBA from the Wharton School of Business and a B.S. from the United States Naval Academy.( He serves on the Board of Directors of Rezolute, Inc., appointed in March 2025.(

Written by Perplexity from public sources.